Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CardioGenesis

This article was originally published in The Gray Sheet

Executive Summary

Disappointing preliminary fourth-quarter results lead to planned cost-cutting measures including a 40% reduction in the firm's sales force (from 30 to 18 reps), and a company-wide headcount cut of 28%. Fourth-quarter revenue is expected in the $2.5 mil. range, with operating losses of about $3.0 mil. The company cites "unfavorable economic conditions" as contributing to lower-than-expected sales of the TMR laser revascularization system. In early 2001, CardioGenesis indicated it would cut or outsource 90% of its work force (1"The Gray Sheet" July 30, 2001, p. 11)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT015967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel